Contributing Member of the Healthcare Councils
Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
GLG News by this Author
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
LABA's Should Never Be first Line Therapy
December 11, 2008
FDA: Long-Acting Asthma Drugs Increase Asthma Risks | online.wsj.com
National asthma guidelines have been clear for years that single drug therapy with a LABA should be minimal. Even with these long standing recommendations, LABA use has remained strong due to signifi9cant MD marketing. Health plans and PBMs have a responsibility to implement electronic drug edits to minimize LABA use.
-
November 24, 2008
Are Costly Diabetes Pills Doing Any Good? | www.pharmalot.com
Our obsession with quick fixes and a lack of focus on lifestyle changes will provide sub-optimal results. Without comparative effectiveness trials, there is no way to gauge the value of these new therapies.
-
Off Label Use Can Be Prevented
November 24, 2008
Use of Antipsychotics in Children Is Criticized | www.nytimes.com
Current PBM adjudication technology can stop a prescription from being a covered benefit when an atypical is being prescribed in the pediatric setting. the dispensing pharmacist would receive a prior authorization required message and a discussion with the prescribing MD would be required. I did this when I was chief pharmacy officer.
-
Who can tolerate these doses and for how long?
November 13, 2008
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com
20 mg of Crestor is a high dose associated in many studies with a higher incidence of side effects. Since compliance is historically poor with any maintenance medication, it will be interesting to see if patients with normal LDL with stay compliant with this statin or any statin in the higher doses in a real world population. It is also important to note that simvastatin, another super-statin is available as a generic and should be used 1st line more often than it is today.
-
November 12, 2008
Pharma need not worry too much about President Obama | www.biovalley.ch
The Obama vision is based on science driving the prescription process. As such, DTC advertising and the sampling of brand name medications will either be restricted or incentives provided to MDs to replace samples with vouchers. PBMs will be required to be absolutely transparent and Medicare Part D will require transparency on rebates and a minimum rebate for the dual eligibles, at a minimum.
-
July 21, 2008
Drug groups prescribe for future growth | www.ft.com
Drug manufacturers must evolve to an outcomes based reimbursement schedule to gain formulary placement and avoid prior authorization and oher utilization management tools
-
July 11, 2008
8-Year-Olds on Statins? A New Plan Quickly Bites Back | www.nytimes.com
Dangers of over-medication. Lack of long term studies. lack of personal and parental responsibility
-
Different reimbursement systems for oral and infusion drugs corrupts the drug use process
July 10, 2008
Pricey Drugs Put Squeeze on Doctors | online.wsj.com
To enhance health care efficiency, MDs should not have to purchase and stock expensive biotech drugs in their office. Drugs should be charged to the health plan or PBM and the drugs should arrive at the MDs office labeled for the particular patient
-
PBMs and Big PhRMA fiddle while the health care system burns
July 9, 2008
Drug groups prescribe for future growth | www.ft.com
Pricing constraints in the US such as Best Price legislation preclude innovative outcomes based solutions from being adopted. CMS should provide waivers to Best Price to enable payers and drug innovators to engage in risk based contracts
Page : 11 to 9 of 9
- Subscribe to Updates
-
This author consults with leading institutions through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.